News

H-E-B, Thrifty White recognized for political involvement at NACDS TSE

BY Ryan Chavis

BOSTON — H-E-B and Thrify White Pharmacy were recognized for their political advocacy and grassroots support at the National Association of Chain Drug Stores Political Involvement Reception during the NACDS Total Store Expo in Boston.  

NACDS chain member H-E-B received the NACDS RxImpact “Leader of the Year” award for its engagement in numerous NACDS RxImpact events. Thrifty White Pharamcy was honored with the NACDS Political Action Committee “Politically Engaged Pharmacy” award in recognition of exceptional commitment to advancing pharmacy through the NACDS-PAC.

“Political and grassroots involvement is so vital for pharmacy to succeed in public policy,” NACDS president and CEO Steven Anderson, IOM, CAE stated.  “We congratulate H-E-B and Thrifty White for their commitment to the NACDS RxImpact program and the NACDS-PAC. Everything we do on behalf of the chain pharmacy industry is done to reinforce our theme of pharmacy being the face of neighborhood healthcare, and these two companies do so much to convey that important message.”    

The NACDS RxImpact grassroots program was launched to further advance pro-patient, pro-pharmacy policies. The program’s many facets — including the NACDS RxImpact Day on Capitol Hill meetings with policymakers in Washington and NACDS RxImpact pharmacy tours bringing members of Congress into pharmacies in their states and districts — are just some of the opportunities to help engage policymakers about the value of pharmacy in improving healthcare delivery, NACDS stated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Nipro Diagnostics gets FDA approval for blood-glucose monitors

BY Ryan Chavis

FORT LAUDERDALE, Fla. — Nipro Diagnostics announced that the Food and Drug Administration approved its True Metrix self-monitoring blood-glucose system, as well as the True Metrix Pro professional monitoring blood-glucose system. The company made the announcement at the National Association of Chain Drug Stores Total Store Expo in Boston.

The meters use pre- and post-meal tags that allow patients to mark results to help better understand how food affects blood glucose. Patients also are able to tie noteworthy events — exercise, medication, sickness and other occasions — to blood glucose readings to determine patterns and trends, helping them to make better decisions in the management of diabetes, the company said.

“It is essential as the store brand leader in diabetes that we continue to innovate from both a technology and a business perspective. The evolving payer landscape, driven by demands of increased clinical performance and economic accountability, has created a market energized in disruption. The True Metrix blood glucose monitoring platform reinforces our commitment to offer an innovative, affordable solution for diabetes patients to lead healthier lives,” Scott Verner, CEO and president of Nipro Diagnostics, said.

True Metrix will be available through retail, mail and distribution channels beginning fourth-quarter 2014.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

FDA approves Iroko’s NSAID for chronic pain

BY David Salazar

PHILADELPHIA — Pharmaceutical company Iroko announced today that capsules of its anti-inflammatory drug Zorvolex had been approved by the Food and Drug Administration. This version of the drug is intended to manage pain for those with chronic osteoarthritis. Zorvolex was approved in the United States in October 2013 for the treatment of mild to moderate acute pain in adults.

“Expanding the use of Zorvolex beyond acute pain to osteoarthritis pain, a chronic condition, is a testament to Iroko’s continued commitment to developing a low dose NSAID portfolio to address a broad range of unmet patient needs,” said John Vavricka, Iroko’s president and CEO, said. “This second approval for Zorvolex continues to lay the groundwork for our future portfolio, which utilizes a new approach to pain management.” 

In reformulating the drug to manage chronic pain, Iroko followed the FDA’s recommendation that non-steroidal anti-inflammatory drugs contain the minimum effective dose that works for the shortest time. The particles of active ingredient diclofenac are smaller than in normal NSAIDs, but absorption isn’t delayed.

“NSAIDs continue to be an integral part of the management for osteoarthritis, the most common type of arthritis, and their use is likely to increase as the U.S. population continues to age and the incidence of osteoarthritis rises,” said Dr. Roy Altman, a rheumatology professor at the University of California, Los Angeles, said. “The approval of Zorvolex is a welcome and meaningful advance and is the first SoluMatrix NSAID option approved by the FDA for osteoarthritis pain.”

Zorvolex for chronic pain is currently available by prescription.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?